Brief: Tonix Pharmaceuticals Presented Data And Analyses Of Tnx-102
12/08/2024 14:02
Aug 12 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS PRESENTED DATA AND ANALYSES OF
TNX-102 SL
TREATMENT EFFECTS ON FIBROMYALGIA, THE PROTOTYPIC NOCIPLASTIC
PAIN SYNDROME, AT THE IASP 2024 WORLD CONGRESS ON PAIN
* FDA GRANTED TNX-102 SL FAST TRACK DESIGNATION FOR
MANAGEMENT OF
FIBROMYALGIA; NDA SUBMISSION ON TRACK FOR H2 2024
Source text for Eikon: ID:nGNX1kY4SS
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview